Shattuck Labs, Inc. (STTK)

Market Cap	430.82M +599.6%
Revenue (ttm)	1,000,000 -82.5%
Net Income	-48.81M
EPS	-0.70
Shares Out	71.56M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	836,839
Open	6.04
Previous Close	5.99
Day's Range	5.75 - 6.25
52-Week Range	0.69 - 6.25
Beta	1.67
Analysts	Buy
Price Target	7.00 (+16.28%)
Earnings Date	Mar 5, 2026

About STTK

Shattuck Labs, Inc., a biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases. The company’s lead product candidate includes SL-325, a DR3 blocking monoclonal antibody, which activates immune responses through binding a single receptor, DR3; and SL-425. It also develops multiple preclinical DR3-based bispecific antibodies for the treatment of inflammatory bowel disease; and a series of bispecific antibodies targeting DR3 and other clinically validated targets. In addition, the company is involv...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 9, 2020
• Employees: 44
• Stock Exchange: NASDAQ
• Ticker Symbol: STTK
• Website: https://www.shattucklabs.com

Financial Performance

In 2025, Shattuck Labs's revenue was $1.00 million, a decrease of -82.52% compared to the previous year's $5.72 million. Losses were -$48.81 million, -35.28% less than in 2024.

Analyst Summary

According to 7 analysts, the average rating for STTK stock is "Buy." The 12-month stock price target is $7.0, which is an increase of 16.28% from the latest price.

Price Target

$7.0

(16.28% upside)

Analyst Consensus: Buy